From: Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates
Emirati-Emiratis | Non-Emirati-Emiratis | |
---|---|---|
Total number | 33 | 33 |
Female/male | 26/7 | 21/12 |
Systemic | 4 (12.2%) | 9 (27.3%) |
Persistent Oligo JIA | 10 (30.3%) | 6 (18.2%) |
Extended Oligo JIA | 2 (6%) | 1 (3%) |
Poly JIA RF-ve | 10 (30.3%) | 10 (30.3%) |
Poly JIA RF + ve | 7 (21.2%) | 5 (15.2%) |
Enthesitis-related JIA | - | 1 (3%) |
Psoriatic | - | 1 (3%) |
Mean time from onset to first appointment with Ped Rheum (months) | 9 | 12.4 |
Range: 1–48 | Range: 1–96 | |
Median time from onset to first appointment with Pediatric rheumatology | 10 months | 14 months |
Oral steroids at diagnosis | 31 (94%) | 32 (97%) |
>2 health professionals seen before pediatric rheumatologist | 31 (94%) | 25 (75.7%) |
Referral to ophthalmology prior to pediatric rheumatology | 7 (21.2%) | 7 (21.2%) |
Uveitis | 3 (9%) | 2 (6%) |
MTX alone | 10 (30.3%) | 5 (15.2%) |
Biologic + MTX treatment | 10 (30.3%) | 15 (45.5%) |
Remission on treatment | 12 (36.3%) | 10 (30.3%) |
Disability | 1 blind (uveitis) | 1 multiple joint deformities |